Breast Cancer: Essex
2026-06-19 · Department of Health and Social Care · 11569 · Official question
Question
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients in Essex with HER2-low metastatic breast cancer who would be eligible for treatment with Enhertu were it to be routinely commissioned.
Answer
In July 2024, the National Institute for Health and Care Excellence (NICE) estimated that approximately 1,000 to 1,500 people would have been eligible for treatment with trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cance...